Transparent Inc., a bio-venture business headquartered here, announced today that it will host a session presenting the most recent results validating Cell-able, a human hepatocyte array kit with the potential to reduce drug development costs and time-to-market for pharmaceutical companies, to attendees of the annual meeting of the Society of Toxicology, in Salt Lake City on March 9 at 9:45 a.m..
Dr. Shin Enosawa, Biochemistry/Division head of the Department of Surgery for Japan’s National Research Institute for Child Health and Development, who has been conducting research with Transparent, will host the session in room 155B of the Salt Palace Convention Center. ToxExpo attendees can also visit Transparent at booth 2108 and view a poster presentation illustrating the most current research data on Cell-able throughout the annual meeting.
The Cell-able array enables the formation, from human liver cells, of 3D structures mimicking liver tissue that sustains functions for two weeks or more, versus current testing methods which maintain cell functions for three days. In addition to extending liver cell life, Cell-able allows researchers to evaluate multiple liver functions in one test plate.
Cell-able is a hepatocyte spheroid array kit that enables the formation of 3D structures that mimic liver tissue on standard culture plates. It provides a novel liver evaluation system for developing new compounds by offering more efficient and advanced testing of new drug pharmacokinetics and safety. Cell-able was developed through a collaboration of Transparent and Toyo Gosei Co., Ltd., one of Japan’s leading manufacturers of photosensitive materials for semiconductors. Transparent provided the cell culturing technology and Toyo Gosei managed plate surface control technology.
Transparent Inc. produces and distributes plates for cell arrays (chips) and specialized culture media. Founded by Yukio Nagasaki (currently professor at the University of Tsukuba) in August 2003 as a bio-venture business, it was the seventh venture business launched by the Tokyo University of Science. The company incorporates bio-nano interface technology, cell culture technology and cell culture control technology to create a core technology that facilitate the use of animal cells in arrays for long-term culture in a highly active state.